Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Analytical Run Sequence and Setup – V 2.0

Posted on By

BA-BE Studies: SOP for Analytical Run Sequence and Setup – V 2.0

Standard Operating Procedure for Analytical Run Sequence and Setup in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/170/2025
Supersedes SOP/BA-BE/170/2022
Page No. Page 1 of 11
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To outline the standardized procedure for setting up and executing the analytical run sequence for LC-MS/MS systems in BA/BE studies, ensuring accurate sample analysis and regulatory compliance.

2. Scope

This SOP applies to all analysts and scientific staff responsible for planning and executing analytical runs on LC-MS/MS systems used in the bioanalysis of plasma samples during bioavailability and bioequivalence studies.

3. Responsibilities

  • Analyst: Prepares and executes the run sequence as per study design and batch layout.
  • Reviewer/Supervisor: Verifies run setup parameters and sequence structure.
  • QA Officer: Audits analytical sequences and records for GxP compliance.
See also  BA-BE Studies: SOP for Managing Female Volunteers in BA/BE Trials - V 2.0

4. Accountability

The Head of Bioanalytical Operations is accountable for ensuring adherence to this SOP during all analytical run setups to maintain data integrity and regulatory consistency.

5. Procedure

5.1 Sequence Design and Naming Convention

  1. Create the run sequence file using the LC-MS/MS software (e.g., Analyst™, MassLynx™, Empower™).
  2. Name each sequence file as per the following convention:
    • Format: [StudyCode]_Seq_[BatchNumber]_YYYYMMDD
    • Example: BE2456_Seq_02_20250417
  3. Save the file in a secure, study-specific folder with backup.

5.2 Sequence Structure and Order

  1. Include the following components in this exact order:
    • System Suitability Test (blank and system check sample)
    • Double blank sample (no analyte, no internal standard)
    • Single blank (no analyte, with internal standard)
    • Calibrators: STD01 to STDx (minimum 6 non-zero concentrations)
    • Quality Control Samples: LQC, MQC, HQC in duplicate
    • Study Samples (randomized and interspersed with QCs)
    • Anchor QCs (at beginning, middle, and end)
    • Final blank to ensure no carryover
  2. Use randomization software to arrange subject samples.
See also  BA-BE Studies: SOP for Observing Post-Dose Adverse Events - V 2.0

5.3 Instrument Method and Tuning File

  1. Select validated instrument method file containing:
    • Retention times
    • MRM transitions
    • Dwell times
  2. Load appropriate tuning/calibration file approved during system readiness check.
  3. Ensure signal intensity of tuning compound meets system suitability criteria.

5.4 Sample Information and Metadata Entry

  1. Enter:
    • Sample ID
    • Sample type (STD, QC, Subject, Blank)
    • Vial position
    • Batch ID
  2. Assign correct processing method and integration parameters.

5.5 Final Review and Run Initiation

  1. Have sequence reviewed by the study supervisor or scientific reviewer using Annexure-1: Analytical Run Checklist.
  2. QA should review run logbook entries, audit trail settings, and lock the sequence file.
  3. Begin run after confirmation of:
    • Correct tray loading
    • Run time within 36 hours
    • Environmental conditions within range

5.6 Run Completion and Documentation

  1. After run completion, perform:
    • Peak integration (auto/manual)
    • System suitability verification
    • Backup of data
  2. Document run performance in Annexure-2: Analytical Run Log.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • LC-MS/MS: Liquid Chromatography-Tandem Mass Spectrometry
  • QC: Quality Control
  • STD: Standard
  • MRM: Multiple Reaction Monitoring
See also  BA-BE Studies: SOP for Scheduling of Pre-Dose Fasting Period - V 2.0

7. Documents

  1. Analytical Run Checklist – Annexure-1
  2. Analytical Run Log – Annexure-2

8. References

  • ICH M10: Bioanalytical Method Validation
  • FDA Guidance for Industry: Bioanalytical Method Validation
  • Internal LC-MS/MS Operation SOP

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Analytical Run Checklist

Parameter Checked Remarks Initials
Correct sequence file loaded Yes Verified SR
Sample tray matched with layout Yes All vials checked RK

Annexure-2: Analytical Run Log

Run Date Batch ID System Used Start Time End Time Analyst
17/04/2025 BE2456-MET-02 Sciex 6500+ 08:30 20:00 Sunita Reddy

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial version New SOP QA Head
17/04/2025 2.0 Sequence layout structure and verification steps added Regulatory update QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Compatibility Studies of Container Closure Systems – V 2.0
Next Post: Analytical Method Development: ATR-FTIR Method SOP – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version